merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>safer option with FDA approval and oversight</answer>

<question_number>2</question_number>
<answer>offers direct online prescriptions and home delivery similar to telehealth companies</answer>

<question_number>3</question_number>
<answer>less oversight and potential safety, quality, and effectiveness issues</answer>

<question_number>4</question_number>
<answer>to regain customers currently using compounded tirzepatide</answer>

<question_number>5</question_number>
<answer>compounding pharmacies can legally produce medications listed as "in shortage" by the FDA</answer>

<question_number>6</question_number>
<answer>removing third-party supply chain entities to offer transparent pricing</answer>

<question_number>7</question_number>
<answer>older Medicare patients may face increased health risks like muscle loss and fractures</answer>

<question_number>8</question_number>
<answer>could position Lilly's FDA-approved vials as safer than compounded alternatives</answer>

<question_number>9</question_number>
<answer>FDA shortage list</answer>

<question_number>10</question_number>
<answer>lower pricing</answer>